# BI-754091 and Afatinib for Refractory Esophageal Squamous Cell Carcinoma (BEAR Study)

> **NCT04839471** · PHASE2 · COMPLETED · sponsor: **National Health Research Institutes, Taiwan** · enrollment: 49 (actual)

## Conditions studied

- Esophageal Squamous Cell Carcinoma (ESCC)

## Interventions

- **DRUG:** BI-754091 plus afatinib

## Key facts

- **NCT ID:** NCT04839471
- **Lead sponsor:** National Health Research Institutes, Taiwan
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-06
- **Primary completion:** 2023-07-24
- **Final completion:** 2024-06-19
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2024-07-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04839471

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04839471, "BI-754091 and Afatinib for Refractory Esophageal Squamous Cell Carcinoma (BEAR Study)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04839471. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*